04.18.13
EMD Serono, Inc., a subsidiary of Merck KGaA, is continuing the expansion of its U.S. presence with an estimated 20% increase in staff though the end of 2014. The expansion will primarily take place at its site in Billerica, MA, which is being renamed EMD Serono Research & Development Institute. The Billerica site provides early stage drug discovery research through to clinical development and medical.
The company has also made appointments within global functional areas at its Rockland and Billerica sites, including the heads of three global Research and Early Development platforms, Immuno-Oncology, Immunology and Neurology. Additionally, heads of global business franchises, and various other strategic leaders within the global operations, are now based in the U.S.
“The U.S. represents one of the fastest growing markets for our company,” said Annalisa Jenkins, head of Global Drug Development and Medical. “Strengthening our presence in the U.S. is central to our ability to deliver innovation and value to our patients and customers. By expanding our footprint within the Boston life sciences cluster of technology and talent, we significantly enhance our competitive position in the U.S. and globally.”
The company has also made appointments within global functional areas at its Rockland and Billerica sites, including the heads of three global Research and Early Development platforms, Immuno-Oncology, Immunology and Neurology. Additionally, heads of global business franchises, and various other strategic leaders within the global operations, are now based in the U.S.
“The U.S. represents one of the fastest growing markets for our company,” said Annalisa Jenkins, head of Global Drug Development and Medical. “Strengthening our presence in the U.S. is central to our ability to deliver innovation and value to our patients and customers. By expanding our footprint within the Boston life sciences cluster of technology and talent, we significantly enhance our competitive position in the U.S. and globally.”